Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Publication date: Available online 23 November 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Brianna Smith, Michael Savona, Rami S. KomrokjiAbstractMyelodysplastic/Myeloproliferative neoplasms (MDS/MPN) are hybrid group of chronic myeloid neoplasms combining features of both MDS and MPN. The world health organization (WHO) classification coined this group designation in 2008 to include chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), juvenile myelomoncoytic leukemia (JMML), refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) as provisional entity, and MDS/MPN unclassified (MDS/MPN-U). In this review we highlight the challenges in diagnosing this group of the diseases, summarize the updates in classification and recent evolving understanding of the genetic landscape. We review risk stratification models and overview the current management largely adapted from current MDS or MPN therapies. We define clinical benefit of therapy based on new proposed response criteria developed specifically for those groups of neoplasms. Finally we introduce future opportunities including the planned international ABN MARRO clinical study led by the MDS/MPN international working group.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research